Market closedNon-fractional
Editas Medicine/EDIT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Editas Medicine
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
Ticker
EDIT
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Cambridge, United States
Employees
265
Website
www.editasmedicine.com
Editas Medicine Metrics
BasicAdvanced
$458M
Market cap
-
P/E ratio
-$2.10
EPS
2.05
Beta
-
Dividend rate
Price and volume
Market cap
$458M
Beta
2.05
Financial strength
Current ratio
4.596
Quick ratio
4.458
Long term debt to equity
7.399
Total debt to equity
11.596
Management effectiveness
Return on assets (TTM)
-25.60%
Return on equity (TTM)
-54.30%
Valuation
Price to revenue (TTM)
6.357
Price to book
1.56
Price to tangible book (TTM)
1.56
Price to free cash flow (TTM)
-2.922
Growth
Revenue change (TTM)
204.52%
Earnings per share change (TTM)
-33.96%
3-year revenue growth (CAGR)
-8.80%
3-year earnings per share growth (CAGR)
-1.44%
What the Analysts think about Editas Medicine
Analyst Ratings
Majority rating from 18 analysts.
Editas Medicine Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$1.1M
-98.17%
Net income
-$62M
229.26%
Profit margin
-5,627.27%
17,861.28%
Editas Medicine Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.56
-$0.55
-$0.23
-$0.76
-
Expected
-$0.76
-$0.57
-$0.54
-$0.66
-$0.70
Surprise
-26.62%
-3.19%
-57.57%
14.34%
-
Editas Medicine News
AllArticlesVideos
Editas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual Congress
GlobeNewsWire·1 month ago
Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress
GlobeNewsWire·1 month ago
Editas Medicine, Inc. (EDIT) RBC Capital Markets Global Healthcare Conference (Transcript)
Seeking Alpha·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Editas Medicine stock?
Editas Medicine (EDIT) has a market cap of $458M as of July 27, 2024.
What is the P/E ratio for Editas Medicine stock?
The price to earnings (P/E) ratio for Editas Medicine (EDIT) stock is 0 as of July 27, 2024.
Does Editas Medicine stock pay dividends?
No, Editas Medicine (EDIT) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Editas Medicine dividend payment date?
Editas Medicine (EDIT) stock does not pay dividends to its shareholders.
What is the beta indicator for Editas Medicine?
Editas Medicine (EDIT) has a beta rating of 2.05. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Editas Medicine stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.